GlobeNewswire

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide

Del

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender.    

The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to the clinic and complete a Phase 1 clinical trial.

"This additional investment will help accelerate our efforts to bring our novel microbicide to market," said Dr. Ian McGowan, Chief Scientific Officer for Orion Biotechnology. "Armed with sufficient capital and a robust preclinical data package, Orion is now positioned to advance OB-002H into the clinic."

Mark Groper, President and CEO of Orion Biotechnology, added; "We are honoured to have been successful in the comprehensive and highly competitive selection process conducted by the National Center for Research and Development.  It is further endorsement of our world-class team of experts as well as the therapeutic and commercial promise of our innovative HIV microbicide product."

About Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world's leading research institutions, such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. Learn more at www.orionbiotechnology.com.

Forward-Looking Statements
This press release contains forward-looking information, which reflects Orion's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Ross MacLeod
Orion Biotechnology 
Canada Ltd
Phone: +1.343.291.1032
info@orionbiotechnology.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Biotechnology Canada Ltd via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Tenaris Convenes General Meeting of Shareholders27.6.2019 00:04:00 CESTPressemelding

LUXEMBOURG, June 26, 2019 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) announces that it has published the convening notice to the General Meeting of Shareholders that will be held on July 29, 2019, at 11:00 a.m. (Central European Time) at Tenaris’s registered office, located at 29, avenue de la Porte-Neuve, 3rd Floor, L-2227 Luxembourg, to consider, and if thought fit, approve the delisting of Tenaris’s shares from the Buenos Aires stock exchange, Bolsas y Mercados Argentinos S.A., through a voluntary withdrawal from listing. The convening notice (which includes the agenda for the meeting and the procedures for attending and/or voting at the meeting) can be downloaded from the Luxembourg Stock Exchange’s website at www.bourse.lu/regulated-information-oam. In addition, the convening notice, together with the total number of shares and voting rights as of the date of the convening notice, and the proxy materials for the meeting (which include t

Acreage Obtains Final Order for Plan of Arrangement with Canopy Growth and Confirms Record Date for Acreage Shareholders Entitled to Receive the Option Premium26.6.2019 23:20:00 CESTPressemelding

NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- On June 21, 2019, Acreage Holdings, Inc. (“Acreage”) (CSE:ACRG.U) (OTC: ACRGF) (FSE: 0ZV) obtained a final order from the Supreme Court of British Columbia approving the previously announced arrangement under section 288 of the Business Corporations Act (British Columbia) with Canopy Growth Corporation (“Canopy Growth”) (TSX:WEED) (NYSE:CGC) (together with Acreage, the “Companies”) (the “Arrangement”). On June 19, 2019, each of Acreage and Canopy Growth received all necessary shareholder approvals in connection with the Arrangement at their respective special shareholder meetings. Pursuant to the Arrangement, Canopy Growth will be provided with the option (the “Canopy Growth Call Option”) to acquire all of the issued and outstanding shares in the capital of Acreage (each, an “Acreage Share”), with a requirement to do so upon a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijua

ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC26.6.2019 23:00:00 CESTPressemelding

LYON, France and CAMBRIDGE, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial, named TRYbeCA2, evaluating its lead product candidate eryaspase for the treatment of first line triple negative breast cancer (TNBC). Following the positive Phase 2 results with eryaspase in second-line metastatic pancreatic cancer, ERYTECH selected triple-negative breast cancer as the next indication to expand the potential use of eryaspase in solid tumors. TNBC is an aggressive and metabolically active form of breast cancer with high rates of symptomatic metastases. A Phase 2/3 clinical trial in first-line metastatic TNBC, named TRYbeCA2, was designed and the Phase 2 part of the trial was launched in Spain, Belgium, Hungary and the United Kingdom. The t

EXIDE TECHNOLOGIES COMPLETES COMPREHENSIVE NEW FINANCING AND RECAPITALIZATION26.6.2019 19:37:00 CESTPressemelding

Milton, GA, June 26, 2019 (GLOBE NEWSWIRE) -- Exide Technologies (or the “Company”) (www.exide.com), a global leader in stored energy solutions for the automotive and industrial markets, today announced the completion of a comprehensive new financing and recapitalization transaction led by the Company’s institutional shareholders which has enhanced the Company’s liquidity, extended debt maturities and deleveraged its balance sheet. Issued $150 million new international notes, net proceeds of approximately $125 million Converted $175 million of existing second lien notes to equity Extended first lien note maturity to 2024 from 2022 in an exchange offer Extended second lien note maturity to 2027 from 2025 in an exchange offer Extended ABL credit facility maturity to July 2021 from January 2020 “We believe this transaction is a great outcome for Exide and is intended to significantly improve Exide’s financial position allowing for further growth and continued reinvestment in our business,

FIDO Alliance Announces New Identity Verification and IoT Initiatives to Expand the Reach and Impact of FIDO Authentication26.6.2019 16:30:00 CESTPressemelding

New working groups formed to secure adjacent technologies that are critical for end-to-end identity lifecycle management WASHINGTON, June 26, 2019 (GLOBE NEWSWIRE) -- IDENTIVERSE -- The FIDO Alliance today announced two new standards and certification initiatives in identity verification and the Internet of Things (IoT). These initiatives build upon the Alliance’s ongoing focus on driving the efficacy and market adoption of FIDO Authentication by addressing adjacent technology areas that leave security vulnerabilities on the web. Specifically, the Alliance aims to strengthen identity verification assurance to support better account recovery, and automate secure device onboarding to remove password use from IoT. The Alliance has formed two new working groups: the Identity Verification and Binding Working Group (IDWG) and the IoT Technical Working Group (IoT TWG) to establish guidelines and certification criteria in these areas. The FIDO Alliance will continue to focus on development and

Enablon’s Sustainable Performance Forum (SPF) Focuses on the Future of EHS, Risk and Sustainability26.6.2019 16:21:00 CESTPressemelding

New Risk, Safety and Sustainability innovations in mobility, IOT integrations, and artificial intelligence (AI) used live on stage with early-adopter customers CHICAGO and PARIS, June 26, 2019 (GLOBE NEWSWIRE) -- Wolters Kluwer’s Enablon, a global leader in EHS, Risk and Sustainability Management software, announced at SPF 2019 new innovations executing on its Industry 4.0 Connected Enterprise strategy. The global SPF conference series leads the industry with more than 1,000 attendees from over 35 countries, 20 industry user groups, 120 expert sessions and 80 customer and partner presentations. At SPF Americas and SPF EMEA, Enablon announced new solutions across its suite of applications in Health & Safety Management, Governance, Risk & Compliance, Environmental Management & Sustainability, Process Safety & Control of Work, and Product Stewardship & Quality. The conferences focused on execution against Enablon’s Industry 4.0 Connected Enterprise vision, announcing new platform innovati